Immunology and Biotherapies
14.9K views | +0 today
Follow
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma. - PubMed - NCBI

LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma. - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
Oncoimmunology. 2016 Oct 7;5(11):e1239005. doi: 10.1080/2162402X.2016.1239005. eCollection 2016.

Abstract Immunotherapy with immune checkpoint molecule-specific monoclonal antibody have obtained encouraging results from preclinical studies and clinical trials, which promoted us to explore whether this kind of immunotherapy could be applicable to head and neck squamous cell carcinoma (HNSCC). Lymphocyte activation gene-3 (LAG-3) is an immune checkpoint control protein that negatively regulates T cells and immune response. Here, using the human tissue samples, we report these findings that LAG-3 is overexpressed on tumor-infiltrating lymphocytes (TILs; p < 0.001) and its overexpression correlates with the high pathological grades, lager tumor size and positive lymph node status in human primary HNSCC. Survival analysis identifies LAG-3 as a prognostic factor independent of tumor size and pathological grades for primary HNSCC patients with negative lymph node status (p = 0.014). Study in immunocompetent genetically defined HNSCC mouse model reports that LAG-3 is upregulated on CD4+ T cells, CD8+ T cells and CD4+Foxp3+ regulatory T cells (Tregs). In vivo study, administration of LAG-3-specific antibody retards tumor growth in a way associated with enhanced systemic antitumor response by potentiating the antitumor response of CD8+ T cells and decreasing the population of immunosuppressive cells. Taken together, our results offer a preclinical proof supporting the immunomodulatory effects of LAG-3 and suggest a potential therapeutic target of immunotherapy for HNSCC.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, December 23, 2016 3:53 AM
Oncoimmunology. 2016 Oct 7;5(11):e1239005. doi: 10.1080/2162402X.2016.1239005. eCollection 2016. LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma. Deng WW1, Mao L1, Yu GT1, Bu LL1, Ma SR1, Liu B2, Gutkind JS3, Kulkarni AB4, Zhang WF2, Sun ZJ
Scooped by Gilbert C FAURE
Scoop.it!

Camels and Llamas Provide Inspiration in the Fight Against Cancer | GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business | GEN

Camels and Llamas Provide Inspiration in the Fight Against Cancer | GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business | GEN | Immunology and Biotherapies | Scoop.it
Researchers flipped the active site of human antibodies to target tumor-promoting matrix metalloproteinases
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Immunotherapy in the Precision Medicine Era: Melanoma and Beyond

Immunotherapy in the Precision Medicine Era: Melanoma and Beyond | Immunology and Biotherapies | Scoop.it
In a Perspective, Mack Su and David Fisher discuss the development of immunotherapies for treatment of melanoma and other cancer types.
more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

Cornell researchers develop chemical probe activated by UV light to control inflammation | Medic Inform

Cornell researchers develop chemical probe activated by UV light to control inflammation | Medic Inform | Immunology and Biotherapies | Scoop.it
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Functional screening for anti-CMV biologics identifies a broadly neutralizing epitope of an essential envelope protein

Functional screening for anti-CMV biologics identifies a broadly neutralizing epitope of an essential envelope protein | Immunology and Biotherapies | Scoop.it
Human cytomegalovirus (CMV) poses a risk for immunosuppressed patients and newborns, with limited treatment options available.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

The antibody that normalizes tumor vessels

The antibody that normalizes tumor vessels | Immunology and Biotherapies | Scoop.it
An important parcel must be delivered to the correct place. It is so important that it can be a question of life or death. However, uneven streets and missing railings risk to bring it off the road and leave it undelivered
more...
Early Drug Development Group's curator insight, December 22, 2016 11:30 AM
A recent study published in Cancer Cell demonstrated that an antibody inhibiting Ang2 and activating Tie2 (ABTAA), two molecules expressed by endothelial cells, restores the structural and functional integrity of tumor blood vessels, allowing the immune cells and drugs to reach the core regions of the tumor more easily. In glioma, lung and breast models, ABTAA delayed tumor growth and displayed synergistic effect when used in combination with conventional treatments. These findings establish that simultaneous Tie2 activation and Ang2 inhibition could be a powerful therapeutic strategy to enhanced delivery of chemotherapeutic agents into tumors.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Research Spotlight: New Frontiers in Cellular Therapies – 360 Degrees of Immuno-oncology - Dana-Farber Cancer Institute | Boston, MA

Research Spotlight: New Frontiers in Cellular Therapies – 360 Degrees of Immuno-oncology - Dana-Farber Cancer Institute | Boston, MA | Immunology and Biotherapies | Scoop.it
New Frontiers in Cellular Therapies: The field of immuno-oncology has recently exploded with novel cellular therapies that elegantly exploit the tumor-antigen recognition and cytotoxic potential of T cells.
Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer — NEJM

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer — NEJM | Immunology and Biotherapies | Scoop.it
Original Article from The New England Journal of Medicine — T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

T-Cell Therapy, a Promising Panacea for Leukemia?

T-Cell Therapy, a Promising Panacea for Leukemia? | Immunology and Biotherapies | Scoop.it
A new study from the Fred Hutchinson Cancer Research Center gives hope to leukemia patients through T-cell therapy, which Dr. Aude Chapuis believes is even better.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Supplement: Treating “Solid” Tumors with CAR T Cells | GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business | GEN

Supplement: Treating “Solid” Tumors with CAR T Cells | GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business | GEN | Immunology and Biotherapies | Scoop.it
The road to developing effective cancer immunotherapies using chimeric antigen receptor (CAR) T cells has been a long and sometimes rocky one.
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis | Immunology and Biotherapies | Scoop.it
Highlights 
• Meta-analysis of the risk of death associated with immune checkpoint inhibitors.
 • CTLA-4 inhibitors are associated with a higher risk of treatment-related death compared with control regimens. 
• The same is not true for PD-1 inhibitors.

Via Krishan Maggon
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Targeting the immune system, not the tumor

Targeting the immune system, not the tumor | Immunology and Biotherapies | Scoop.it
One of the most exciting areas of cancer research today is immuno-oncology.
Via Krishan Maggon
Gilbert C FAURE's insight:
obviously
more...
No comment yet.
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Camelid and shark single domain antibodies: structural features and therapeutic potential

Camelid and shark single domain antibodies: structural features and therapeutic potential | Immunology and Biotherapies | Scoop.it

Highlights • Camelids and sharks comprise heavy chain-only antibodies devoid of light chains. • Their variable domains are able to address cryptic and recessed epitopes. • These variable domains possess beneficial physicochemical properties. • Several of these antibody domains are currently under investigation in the clinic.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, December 21, 2016 5:19 AM
Current Opinion in Structural Biology Volume 45, August 2017, Pages 10–16
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Immunotherapy Could Eradicate A Third of Cancer

Immunotherapy Could Eradicate A Third of Cancer | Immunology and Biotherapies | Scoop.it
#Immunotherapy Eradicate A Third of #Cancers #Jimmy #Carter #Bloomberg #Parker #metastatic #melanoma #lung #bladder https://t.co/fyyq7AVVbG
Via Krishan Maggon
more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells

more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Frontiers | Allorecognition by T Lymphocytes and Allograft Rejection | Alloimmunity and Transplantation

Frontiers | Allorecognition by T Lymphocytes and Allograft Rejection | Alloimmunity and Transplantation | Immunology and Biotherapies | Scoop.it
Recognition of donor antigens by recipient T cells in secondary lymphoid organs initiates the adaptive inflammatory immune response leading to the rejection of allogeneic transplants. Allospecific T cells become activated through interaction of their T cell receptors with intact allogeneic MHC molecules on donor cells (direct pathway) and/or donor peptides presented by self-MHC molecules on recipient antigen presenting cells (APCs) (indirect pathway). In addition, recent studies show that alloreactive T cells can be also stimulated through recognition of allogeneic MHC molecules displayed on recipient APCs (MHC cross-dressing) after their transfer via cell-cell contact or through microvesicles (semi-direct pathway). The specific allorecognition pathway used by T cells is dictated by intrinsic and extrinsic factors to the allograft and can influence the nature and magnitude of the alloresponse and rejection process. Consequently, various organs and tissues such as skin, cornea and solid organ transplants are recognized differently by pro-inflammatory T cells through these distinct pathways, which may explain why these grafts are rejected in a different fashion. On the other hand, the mechanisms by which anti-inflammatory regulatory T cells (Tregs) recognize alloantigen and promote transplantation tolerance are still unclear. It is likely that thymic Tregs are activated through indirect allorecognition while peripheral Tregs recognize alloantigens in a direct fashion. As we gain insights into the mechanisms underlying allorecognition by pro-inflammatory and regulatory T cells, novel strategies are being designed to prevent allograft rejection in the absence of ongoing immunosuppressive drug treatment in patients.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Immunological properties of gold nanoparticles - Chemical Science (RSC Publishing)

Immunological properties of gold nanoparticles - Chemical Science (RSC Publishing) | Immunology and Biotherapies | Scoop.it
In the past decade, gold nanoparticles have attracted strong interest from the nanobiotechnological community owing to the significant progress made in robust and easy-to-make synthesis technologies, in surface functionalization, and in promising biomedical applications. These include bioimaging, gene diagnostics,
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Frontiers | Advances in Therapeutic Fc Engineering – Modulation of IgG-Associated Effector Functions and Serum Half-life | Vaccines and Molecular Therapeutics

Frontiers | Advances in Therapeutic Fc Engineering – Modulation of IgG-Associated Effector Functions and Serum Half-life | Vaccines and Molecular Therapeutics | Immunology and Biotherapies | Scoop.it
Today monoclonal immunoglobulin gamma (IgG) antibodies have become a major option in cancer therapy especially for the patients with advanced or metastatic cancers. Efficacy of monoclonal antibodies (mAbs) are achieved through both its antigen binding fragment (Fab) and crystallizable fragment (Fc). Fab can specifically recognize tumor associated antigen (TAA) and thus modulate TAA-linked downstream signaling pathways that may lead to inhibition of tumor growth, induction of tumor apoptosis and differentiation. The Fc region can further improve mAbs’ efficacy by mediating effector functions such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and antibody dependent cell-mediated phagocytosis (ADCP). Moreover, Fc is the region interacting with the neonatal Fc receptor (FcRn) in a pH-dependent manner that can slow down IgG’s degradation and extend its serum half-life. Loss of the antibody Fc region dramatically shortens its serum half-life and weakens its anti-cancer effects. Given the essential roles that the Fc region plays in the modulation of the efficacy of mAb in cancer treatment, Fc engineering has been extensively studied in the past years. This review focuses on the recent advances in therapeutic Fc engineering that modulates its related effector functions and serum half-life. We also discuss the progress made in aglycosylated mAb development that may substantially reduce cost of manufacture but maintain similar efficacies as conventional glycosylated mAb. Finally, we highlight several Fc engineering based mAbs under clinical trials.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Generation of Immunity against Pathogens via Single-Domain Antibody–Antigen Constructs

Joao N. Duarte, Juan J. Cragnolini, Lee Kim Swee, Angelina M. Bilate, Justin Bader, Jessica R. Ingram, Ali Rashidfarrokhi, Tao Fang, Ariën Schiepers, Leo Hanke and Hidde L. Ploegh + Author Affiliations Whitehead Institute, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142 Address correspondence and reprint requests to Dr. Hidde L. Ploegh, Whitehead Institute, Department of Biology, Massachusetts Institute of Technology, 9 Cambridge Center, Cambridge, MA 02142. E-mail address: ploegh@wi.mit.edu
Gilbert C FAURE's insight:
Abstract mAbs specific for surface proteins on APCs can serve as Ag-delivery vehicles that enhance immunogenicity. The practical use of such constructs is limited by the challenge of expressing and modifying full-sized mAbs. We generated single-domain Ab fragments (VHHs) specific for class II MHC (MHCII), CD11b, and CD36. VHH sequences were modified by inclusion of a C-terminal sortase motif to allow site-specific conjugation with various Ag payloads. We tested T cell activation using VHHs that target distinct APC populations; anti-MHCII adducts elicited strong activation of CD4+ T cells, whereas anti-CD11b showed CD8+ T cell activation superior to targeting via MHCII and CD36. Differences in Ag presentation among constructs were unrelated to dendritic cell subtype or routing to acidic compartments. When coupled to antigenic payloads, anti-MHCII VHH primed Ab responses against GFP, ubiquitin, an OVA peptide, and the α-helix of influenza hemagglutinin’s stem; the last afforded protection against influenza infection. The versatility of the VHH scaffold and sortase-mediated covalent attachment of Ags suggests their broader application to generate desirable immune responses.
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Immunotherapy

Immunotherapy | Immunology and Biotherapies | Scoop.it
Learn about our #immunotherapy expertise here: https://t.co/wVvyPkn8r5 https://t.co/I03O4qEzJ7
Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Tweet from @TrendsImmuno

Trends in Immunology on Twitter https://t.co/mjmpowbuJ1
Gilbert C FAURE's insight:
controlling cells ith light
more...
No comment yet.
Suggested by LIGHTING
Scoop.it!

Researchers load nanocarriers to deliver chemotherapy drugs and imaging molecules to tumors

Researchers load nanocarriers to deliver chemotherapy drugs and imaging molecules to tumors | Immunology and Biotherapies | Scoop.it
A conundrum of cancer is the tumor's ability to use our bodies as human shields to deflect treatment.
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

ASH 2016: Tackling Blood Cancers with Immunotherapy

ASH 2016: Tackling Blood Cancers with Immunotherapy | Immunology and Biotherapies | Scoop.it
Updates from our blog: Cancer Research Institute's work to advance immune-based cancer treatments (immunotherapy), the most innovative and promising area of cancer research today.
Via Krishan Maggon
more...
No comment yet.